TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Click for best price
Market Analysis and Insights: Global Kidney Cancer Drugs Market
The global Kidney Cancer Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Kidney Cancer Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Kidney Cancer Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Kidney Cancer Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Kidney Cancer Drugs market.
Global Kidney Cancer Drugs Scope and Market Size
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Due to the COVID-19 pandemic, the global Kidney Cancer Drugs market size is estimated to be worth US$ 3970.1 million in 2022 and is forecast to a readjusted size of US$ 5501.9 million by 2030 with a CAGR of 4.3% during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Kidney Cancer Drugs market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Kidney Cancer Drugs landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
This report focuses on Kidney Cancer Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Kidney Cancer Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Kidney Cancer Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2018 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Segment by Application
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
The information for each competitor/Company Profile includes:
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Kidney Cancer Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Kidney Cancer Drugs, with price, sales, revenue, and global market share of Kidney Cancer Drugs from 2019 to 2022.
Chapter 3, the Kidney Cancer Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Kidney Cancer Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Kidney Cancer Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Kidney Cancer Drugs.
Chapter 13, 14, and 15, to describe Kidney Cancer Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
Reasons to Purchase this Report:
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes | Report Details |
|---|---|
| Report Title | Global Kidney Cancer Drugs Market Research Report 2023 |
| Historical Year | 2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year | 2021 |
| Forecast Year | 2029 |
| Number of Pages | 117 Pages |
| Customization Available | Yes, the report can be customized as per your need. |
Frequently Asked Questions ?
